GOSSAMER BIO INC (GOSS) Stock Price, Quote, News and Overview
NASDAQ:GOSS - Nasdaq - US38341P1021 - Common Stock - Currency: USD
GOSS Quote, Performance and Key Statistics
1.4
-0.13 (-8.5%)
The current stock price of GOSS is 1.4 USD. In the past month the price increased by 58.03%. In the past year, price increased by 7.69%.
GOSS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About GOSS
Company Profile
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company is headquartered in San Diego, California and currently employs 135 full-time employees. The company went IPO on 2019-02-08. The firm is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways. In addition to PAH, seralutinib holds the potential as a therapeutic option for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Company Info
GOSSAMER BIO INC
3013 Science Park Rd
San Diego CALIFORNIA 92121 US
CEO: Faheem Hasnain
Employees: 135
Company Website: https://www.gossamerbio.com/
Investor Relations: https://ir.gossamerbio.com/
Phone: 18589220718
GOSSAMER BIO INC / GOSS FAQ
What is the stock price of GOSSAMER BIO INC today?
The current stock price of GOSS is 1.4 USD. The price decreased by -8.5% in the last trading session.
What is the ticker symbol for GOSSAMER BIO INC stock?
The exchange symbol of GOSSAMER BIO INC is GOSS and it is listed on the Nasdaq exchange.
On which exchange is GOSS stock listed?
GOSS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GOSSAMER BIO INC stock?
15 analysts have analysed GOSS and the average price target is 7.76 USD. This implies a price increase of 454.23% is expected in the next year compared to the current price of 1.4. Check the GOSSAMER BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GOSSAMER BIO INC worth?
GOSSAMER BIO INC (GOSS) has a market capitalization of 317.24M USD. This makes GOSS a Small Cap stock.
How many employees does GOSSAMER BIO INC have?
GOSSAMER BIO INC (GOSS) currently has 135 employees.
What are the support and resistance levels for GOSSAMER BIO INC (GOSS) stock?
GOSSAMER BIO INC (GOSS) has a support level at 1 and a resistance level at 1.49. Check the full technical report for a detailed analysis of GOSS support and resistance levels.
Should I buy GOSSAMER BIO INC (GOSS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GOSS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GOSS, evaluating the profitability, health, valuation and growth aspects
- GOSSAMER BIO INC (GOSS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GOSSAMER BIO INC (GOSS) Sales and EPS estimates to see what analysts future expectations are.
- GOSSAMER BIO INC (GOSS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GOSSAMER BIO INC (GOSS) Insider and Institutional Ownership to learn about the owners and their transactions.
- GOSSAMER BIO INC (GOSS) Stock Chart to make your own analysis
- GOSSAMER BIO INC (GOSS) Latest news and press-releases to stay up to date.
Does GOSSAMER BIO INC (GOSS) stock pay dividends?
GOSS does not pay a dividend.
When does GOSSAMER BIO INC (GOSS) report earnings?
GOSSAMER BIO INC (GOSS) will report earnings on 2025-03-21, after the market close.
What is the Price/Earnings (PE) ratio of GOSSAMER BIO INC (GOSS)?
GOSSAMER BIO INC (GOSS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.32).
What is the Short Interest ratio of GOSSAMER BIO INC (GOSS) stock?
The outstanding short interest for GOSSAMER BIO INC (GOSS) is 2.65% of its float. Check the ownership tab for more information on the GOSS short interest.
GOSS Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to GOSS. When comparing the yearly performance of all stocks, GOSS is one of the better performing stocks in the market, outperforming 94.83% of all stocks.
GOSS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to GOSS. Both the profitability and financial health of GOSS have multiple concerns.
GOSS Financial Highlights
Over the last trailing twelve months GOSS reported a non-GAAP Earnings per Share(EPS) of -0.32. The EPS increased by 81.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.42% | ||
| ROE | -132.35% | ||
| Debt/Equity | 3.64 |
GOSS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to GOSS. The Buy consensus is the average rating of analysts ratings from 15 analysts.